1-20 of 38
Günter Fingerle-Rowson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase

David Belada, MD PhD, Grzegorz S. Nowakowski, MD, Juan Miguel Bergua Burgues, MD, Marc André, MD, Katerina Kopeckova, MD, Don A. Stevens, MD, Marek Trněný, MD Prof, Ernesto Pérez Persona, Petra Pichler, Pia Klöpfer, Bettina Brackertz, Emanuel Lohrmann, MD, Anirban Lahiry, Neha Shah, Günter Fingerle-Rowson, MDPhD, Wolfram Brugger, John M. Burke, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-139788
Published: 2020
Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

John M Burke, MD, Marc André, Bruce D. Cheson, MD, Johannes Duell, MD, Grzegorz Nowakowski, MD, Andreas Rosenwald, MD, Gilles A. Salles, MD PhD, Jeff P. Sharman, MD, Philipp Bernhard Staber, MD PhD, Marek Trněný, MD, Jason R. Westin, MD, Wolfram Brugger, Günter Fingerle-Rowson, MD PhD, Magdalena Klanova, Guido Würth, PhD, Lorenz Truemper, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2877.
https://doi.org/10.1182/blood-2019-128021
Published: 2019
Journal Articles

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Clinical Trials & Observations
Anton W. Langerak, Matthias Ritgen, Valentin Goede, Sandra Robrecht, Jasmin Bahlo, Kirsten Fischer, Michael Steurer, Marek Trněný, Stephen P. Mulligan, Ulrich J. M. Mey, Kerstin Trunzer, Günter Fingerle-Rowson, Kathryn Humphrey, Stephan Stilgenbauer, Sebastian Böttcher, Monika Brüggemann, Michael Hallek, Michael Kneba, Jacques J. M. van Dongen
Journal: Blood
Blood (2019) 133 (5): 494–497.
https://doi.org/10.1182/blood-2018-03-839688
Published: 2019
Includes: Supplemental data
Journal Articles

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Clinical Trials & Observations
Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong, Jie Jin, Won Seog Kim, Yok Lam Kwong, Marion G. Peters, Yasuhito Tanaka, Andrew D. Zelenetz, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai
Journal: Blood
Blood (2019) 133 (2): 137–146.
https://doi.org/10.1182/blood-2018-04-848044
Published: 2019
Includes: Supplemental data
Journal Articles

FcmR Shapes BCR Signaling in IgM-Positive Leukemia

Alexandra da Palma Guerreiro, PhD, Cornelia Dorweiler, Ismini Halmer, Olaf Merkel, Elena Maria Hartmann, MD, Valeska Berg, PhD, Nina Reinart, Günter Fingerle-Rowson, MD PhD, Gero Knittel, MSc, Christian Pallasch, MD, Andreas Rosenwald, Christian Reinhardt, MD, Clemens-Martin Wendtner, Michael Hallek, MD, Lukas P. Frenzel, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2620.
https://doi.org/10.1182/blood-2018-99-118352
Published: 2018
Journal Articles

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Clinical Trials & Observations
Natalie Dimier, Paul Delmar, Carol Ward, Rodica Morariu-Zamfir, Günter Fingerle-Rowson, Jasmin Bahlo, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Jacques J. M. van Dongen, Matthias Ritgen, Sebastian Böttcher, Anton W. Langerak, Michael Kneba, Michael Hallek
Journal: Blood
Blood (2018) 131 (9): 955–962.
https://doi.org/10.1182/blood-2017-06-792333
Published: 2018
Includes: Supplemental data
Journal Articles

Greater Efficacy and Potency of Obinutuzumab Compared with Rituximab in Chronic Lymphocytic Leukemia Patients Confirmed By a Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Model

Kubra Kamisoglu, Alex Phipps, Candice Jamois, Vincent Buchheit, Georgina Meneses-Lorente, Günter Fingerle-Rowson, Jonathan Wagg, Donald E Mager
Journal: Blood
Blood (2017) 130 (Supplement 1): 1267.
https://doi.org/10.1182/blood.V130.Suppl_1.1267.1267
Published: 2017
Journal Articles

Influence of Baseline Disease Characteristics and Exposure to Obinutuzumab on Clinical Outcome in Patients with Previously Untreated Advanced Follicular Lymphoma Treated with Obinutuzumab-Based Immunochemotherapy in the GALLIUM Trial

Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, Pauline Baumlin, Denis Sahin, Guillaume Cartron, Robert Marcus, Wolfgang Hiddemann, MD PhD, John F Seymour, MBBS, PhD, Jonathan C Strefford, PhD, Georgina Meneses-Lorente, Nicolas Frey, Günter Fingerle-Rowson
Journal: Blood
Blood (2017) 130 (Supplement 1): 3848.
https://doi.org/10.1182/blood.V130.Suppl_1.3848.3848
Published: 2017
Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

Anas Younes, MD, Burke M. John, Catherine S Diefenbach, Silvia Ferrari, Cyrus Kahn, Jeffrey P. Sharman, MD, Monica Tani, Chaitra S. Ujjani, MD, Umberto Vitolo, MD, Sam Yuen, Paul Woodard, Kirsten Mundt, Günter Fingerle-Rowson, Surya Chitra, Gila Sellam, Rodica Morariu-Zamfir, Michael Gilbertson
Journal: Blood
Blood (2017) 130 (Supplement 1): 481.
https://doi.org/10.1182/blood.V130.Suppl_1.481.481
Published: 2017
Journal Articles

A Simulation Analysis to Evaluate the Effect of Prospective Biomarker Testing on Progression-Free Survival (PFS) in DLBCL

Edith Szafer-Glusman, Juan Liu, Franklin V. Peale, Jr., Thalia A. Farazi, Jill Ray, Carsten Horn, Mikkel Z. Oestergaard, Martin Kornacker, Laurie H. Sehn, MDMPH, Günter Fingerle-Rowson, Jeffrey M. Venstrom, Michelle Byrtek, Elizabeth Punnoose
Journal: Blood
Blood (2017) 130 (Supplement 1): 419.
https://doi.org/10.1182/blood.V130.Suppl_1.419.419
Published: 2017
Journal Articles

Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials

Magdalena Klanova, MD, Mikkel Z. Oestergaard, Marek Trněný, MD PhD, Wolfgang Hiddemann, MD PhD, Robert Marcus, Laurie H. Sehn, MDMPH, Umberto Vitolo, MD, Alexandra Bazeos, Valentin Goede, MD, Harald Zeuner, Andrea Knapp, Denis Sahin, Nathalie Danesi, Christopher Bolen, Susan Robson, Jeffrey M. Venstrom, Tina Nielsen, Günter Fingerle-Rowson
Journal: Blood
Blood (2017) 130 (Supplement 1): 727.
https://doi.org/10.1182/blood.V130.Suppl_1.727.727
Published: 2017
Journal Articles

Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study

Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, MDMPH, David Belada, Angelo-Michele Carella, Neil Chua, Eva Gonzalez-Barca, Xiaonan Hong, Antonio Pinto, MD, Yuankai Shi, Yoichi Tatsumi, Günter Fingerle-Rowson, Andrea Knapp, Federico Mattiello, Tina Nielsen, Gila Sellam, Denis Sahin, Umberto Vitolo, MD, Marek Trněný, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 824.
https://doi.org/10.1182/blood.V130.Suppl_1.824.824
Published: 2017
Journal Articles

Systematic Analysis of the Prognostic Impact of Somatic Mutations in Diffuse Large B-Cell Lymphoma (DLBCL) with Evaluation of Cell-of-Origin Dependence: Results from the Phase 3 GOYA Trial in Previously Untreated DLBCL

Christopher Bolen, Magdalena Klanova, MD, Marek Trněný, MD PhD, Laurie H. Sehn, MDMPH, Umberto Vitolo, MD, Maurizio Martelli, Günter Fingerle-Rowson, Tina Nielsen, Georg Lenz, Mikkel Z. Oestergaard
Journal: Blood
Blood (2017) 130 (Supplement 1): 2729.
https://doi.org/10.1182/blood.V130.Suppl_1.2729.2729
Published: 2017
Journal Articles

High Expression of Programmed Death-Ligand 1 (PD-L1) Correlates with Macrophage Gene Expression and Is Associated with Prolonged Progression-Free Survival (PFS) in Patients (pts) with First-Line (1L) Diffuse Large B-Cell Lymphoma (DLBCL)

Ronald McCord, Christopher Bolen, Hartmut Koeppen, Edward E. Kadel, III, Günter Fingerle-Rowson, Mikkel Z. Oestergaard, Jeffrey M. Venstrom
Journal: Blood
Blood (2017) 130 (Supplement 1): 195.
https://doi.org/10.1182/blood.V130.Suppl_1.195.195
Published: 2017
Journal Articles

Managing the Risk of Hepatitis B Virus Reactivation in Patients with B-Cell Lymphomas Treated with Obinutuzumab or Rituximab Immunochemotherapy

Shigeru Kusumoto, MD, Luca Arcaini, MD, Xiaonan Hong, Jie Jin, Won Seog Kim, MD, Ph. D., Yok Lam Kwong, Marion Peters, Yasuhito Tanaka, Andrew D. Zelenetz, MD PhD, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2823.
https://doi.org/10.1182/blood.V130.Suppl_1.2823.2823
Published: 2017
Journal Articles

RPS15 mutations and Treatment Outcome in Chronic Lymphocytic Leukemia - Results from the CLL11 Phase III Trial (Chlorambucil (Clb) with or without the Addition of Rituximab (R) or Obinutuzumab (GA101, G)) of the German CLL Study Group

Sven Estenfelder, MD, Ann-Kathrin Holland-Letz, Eugen Tausch, MD, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Valentin Goede, MD, Veronika Opatrna, MD, Matthias Ritgen, Jacques JM van Dongen, Anton W Langerak, Günter Fingerle-Rowson, MD PhD, Michael Kneba, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1738.
https://doi.org/10.1182/blood.V130.Suppl_1.1738.1738
Published: 2017
Journal Articles

Mode of Progression after First Line Treatment Correlates with Outcome of Chronic Lymphocytic Leukemia (CLL)

Othman Al-Sawaf, MD, Alexandra Bazeos, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Anna Maria Fink, MD, Julia Von Tresckow, Paula Cramer, MD, Petra Langerbeins, MD, Nadine Kutsch, MD, Kathryn Humphrey, PhD, Günter Fingerle-Rowson, MD PhD, Stephan Stilgenbauer, MD PhD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD, Valentin Goede, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1740.
https://doi.org/10.1182/blood.V130.Suppl_1.1740.1740
Published: 2017
Journal Articles

Early Disease Progression Predicts Poorer Survival in Patients with Follicular Lymphoma (FL) in the GALLIUM Study

Aino Launonen, Wolfgang Hiddemann, MD PhD, Ulrich Duenzinger, Günter Fingerle-Rowson, Tina Nielsen, Robert Marcus
Journal: Blood
Blood (2017) 130 (Supplement 1): 1490.
https://doi.org/10.1182/blood.V130.Suppl_1.1490.1490
Published: 2017
Journal Articles

Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Valentin Goede, MD, Eugen Tausch, MD, Sven Estenfelder, MD, Veronika Opatrna, MD, Matthias Ritgen, Jacques JM van Dongen, Anton W Langerak, Günter Fingerle-Rowson, MD PhD, Michael Kneba, MD, Kirsten Fischer, MD, Michael J. Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1708.
https://doi.org/10.1182/blood.V130.Suppl_1.1708.1708
Published: 2017
Journal Articles

Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase 3 GOYA Trial

Mikkel Z. Oestergaard, Christopher Bolen, Federico Mattiello, Maurizio Martelli, Laurie H. Sehn, MDMPH, Marek Trněný, MD PhD, Alexandar Tzankov, Umberto Vitolo, MD, Tina Nielsen, Rodica Morariu-Zamfir, Günter Fingerle-Rowson, Georg Lenz
Journal: Blood
Blood (2017) 130 (Supplement 1): 1543.
https://doi.org/10.1182/blood.V130.Suppl_1.1543.1543
Published: 2017